Whitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Whitehawk Therapeutics (Nasdaq: WHWK) announced that Dave Lennon, PhD, President and CEO, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 at 8:40 AM ET.

Rhea-AI Summary

Whitehawk Therapeutics (Nasdaq: WHWK) announced that Dave Lennon, PhD, President and CEO, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 at 8:40 AM ET. The company is a clinical-stage oncology therapeutics firm focused on antibody drug conjugates (ADC).

A live webcast will be available via the company's investor relations website and will be replayable for approximately 30 days after the presentation.

Argus Feb 18 session

+2.04% close to close Open Argus

Details

News Market Reaction – WHWK

On Feb 18, the day this news came out, WHWK closed 2.04% above the previous close.

Data tracked by StockTitan Argus for the Feb 18 session.

Key Figures

Current price: $2.94 52-week range: $1.39–$3.7699 Cash & investments: $162.6M +5 more

Current price

$2.94

Pre-news price for WHWK

52-week range

$1.39–$3.7699

52-week low and high for WHWK

Cash & investments

$162.6M

As of Sept 30, 2025 (Q3 2025 10-Q)

Q3 2025 net loss

$17.7M

Quarter ended Sept 30, 2025

Stock options granted

650,000 shares at $2.26

CMO equity grant on Dec 1, 2025 (Form 4)

RSUs granted

55,309 RSUs

CMO equity grant on Dec 1, 2025 (Form 4)

Beneficial ownership

2,819,215 shares (5.98%)

Coastlands Schedule 13G as of Aug 4, 2025

Shares outstanding

47,128,362

As of Nov 4, 2025 (10-Q)

Historical Context

5 past events · Latest: Jan 08

5 events

1. Jan 08

   IND clearance update

   24h Move

   +1.5%

   FDA IND clearance for HWK-007 and IND submission for HWK-016.

2. Dec 01

   Executive appointment

   24h Move

   -3.4%

   Appointment of experienced oncology CMO Margaret Dugan, MD.

3. Nov 26

   Conference participation

   24h Move

   +7.0%

   Participation in Piper Sandler healthcare conference with webcast access.

4. Nov 11

   Conference presentation

   24h Move

   +2.3%

   Jefferies Global Healthcare Conference presentation with 30-day replay.

5. Nov 06

   Quarterly earnings

   24h Move

   -6.7%

   Q3 2025 financials with higher cash balance and wider net loss.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

antibody drug conjugate, adc

2 terms

antibody drug conjugate medical

"to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments"

An antibody drug conjugate is a targeted medical treatment that combines a special antibody with a powerful drug, allowing precise delivery of the medicine directly to cancer cells or other harmful cells in the body. For investors, it represents a sophisticated approach to therapy that could improve treatment effectiveness and reduce side effects, potentially leading to significant growth opportunities in the biotech and pharmaceutical sectors.

adc medical

"to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments"

An antibody-drug conjugate (ADC) is a targeted cancer medicine that pairs an antibody that recognizes specific markers on tumor cells with a potent cell-killing drug, connected so the toxic payload is delivered directly to the cancer. For investors, ADCs matter because successful ADCs can improve patient outcomes and reduce side effects compared with traditional chemotherapy, shaping clinical trial success, regulatory approval chances, commercial demand, and a company’s valuation much like a guided missile versus a general bomb.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MORRISTOWN, N.J., Feb. 18, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 8:40 AM EST.

A live webcast of the presentation can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.

About Whitehawk Therapeutics
Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.

Contact:
IR@whitehawktx.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference-302691346.html

SOURCE Whitehawk Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Whitehawk Therapeutics (WHWK) present at the Oppenheimer conference?

Whitehawk Therapeutics will present on February 25, 2026 at 8:40 AM ET. According to the company, Dave Lennon, PhD, President and CEO, will deliver the presentation at that scheduled time.

How can investors watch the WHWK presentation at Oppenheimer on February 25, 2026?

Investors can watch a live webcast via Whitehawk Therapeutics' investor relations website. According to the company, the webcast will also be available for replay for about 30 days after the event.

Who is presenting for Whitehawk Therapeutics (WHWK) at the Oppenheimer 2026 conference?

Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics, will present at the conference. According to the company, he will represent the clinical-stage oncology firm during the session.

What topics will Whitehawk Therapeutics (WHWK) likely cover in the Oppenheimer conference presentation?

The presentation will focus on Whitehawk's clinical-stage oncology work and antibody drug conjugate (ADC) programs. According to the company, the discussion will center on their ADC approach and clinical development progress.

Will the WHWK Oppenheimer presentation be available after February 25, 2026?

Yes, the presentation replay will be available for approximately 30 days following the event. According to the company, the webcast replay can be accessed via the investor relations website during that period.